Teva Sued for Allegedly Blocking Generic EpiPen

Teva Pharmaceutical was hit with a class action lawsuit for an alleged deal with Viatris (formerly Mylan) to delay marketing of Teva’s generic EpiPen.

The alleged deal was in exchange for Viatris holding off marketing its generic narcolepsy competitor to Teva’s Nuvigil, according to the complaint filed in U.S. District Court in Kansas City, Kan. 

UHA Health Insurance claims that it “purchased, paid and/or provided reimbursement for EpiPen products, other than for resale, at supracompetitive prices in Arizona, California, Hawaii, Nevada, New York, Oregon and Tennessee.”

Viatris and Pfizer have settled previous lawsuits — for $264 million and $345 million — to resolve class action antitrust claims alleging a scheme to delay generic competition to the EpiPen allergy treatment and charge higher prices. However, those suits didn’t include Teva.